# Exploring Acute Pancreatitis After Orlistat Use: A Case Report

## TL;DR

This case report explores a possible link between orlistat use and acute pancreatitis in a young woman.

## Contribution

The novelty lies in presenting a specific case and reviewing the association between orlistat therapy and acute pancreatitis.

## Key findings

- A 23-year-old female developed acute pancreatitis after starting orlistat.
- The study reviews clinical cases and risk factors linking orlistat to acute pancreatitis.
- The analysis suggests a potential correlation between orlistat therapy and acute pancreatitis.

## Abstract

Orlistat is an FDA-approved medication for obesity management that functions as a pancreatic lipase inhibitor. This medication is accessible without a prescription in numerous developed nations. As its utilization rises, the likelihood of experiencing adverse events also increases. A thorough understanding of these events is crucial for making informed decisions and ensuring effective management. We describe the case of a 23-year-old female who presented with acute pancreatitis after she started orlistat. We reviewed the association between orlistat use and acute pancreatitis, analyzing clinical cases and potential risk factors. By examining available medical literature and case studies, our study aims to provide insights into the correlation between orlistat therapy and the manifestation of acute pancreatitis.